Drugs that contain Ticagrelor

1. Drug name - BRILINTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46276 ASTRAZENECA Triazolo(4,5-D)pyrimidine compounds
Oct, 2024

(1 year, 10 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE46276

(Pediatric)

ASTRAZENECA Triazolo(4,5-D)pyrimidine compounds
Apr, 2025

(2 years from now)

US8425934 ASTRAZENECA Pharmaceutical compositions
Apr, 2030

(7 years from now)

US8425934

(Pediatric)

ASTRAZENECA Pharmaceutical compositions
Oct, 2030

(7 years from now)

US10300065 ASTRAZENECA Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction
Jan, 2036

(13 years from now)

US10300065

(Pediatric)

ASTRAZENECA Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction
Jul, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Nov 5, 2023
Pediatric Exclusivity (PED) Nov 28, 2023

Market Authorisation Date: 20 July, 2011

Treatment: Reducing the rate of cardiovascular death, myocardial infarction (mi), and stroke in a patient receiving 75-100 mg aspirin daily with a history of mi by administering 60 mg ticagrelor twice daily; Reducing the rate of cardiovascular death, myocardial infarction, and stroke in a patient receiving 75-100 mg aspirin daily and having or who had acute coronary syndrome by administering 60 mg ticagrelor twice daily

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
60MG TABLET;ORAL Prescription
90MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in